Sign in to view content

Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2

Dean Eliott, MD

Video
Published 2025

Related

Types of Strokes Seen in Patients
Sophie Jane Bakri, MD
Updates from the Field
2017
Pooled Clinical Trial Safety Data of Neurotrophic Factorâ€“Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
Paul S. Bernstein, MD, PhD
Annual Meeting Talks
2024
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Annual Meeting Talks
2019

Category: Retinal Vascular Disease

See more